40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Project Information

BRIGHT

Grant agreement ID: 867873

DOI

10.3030/867873

Project closed

EC signature date 26 April 2019

Start date 1 May 2019

End date 30 September 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

OPTOCEUTICS APS
Denmark

Periodic Reporting for period 1 - BRIGHT (40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease)

Reporting period: 2019-05-01 to 2019-09-30

Summary of the context and overall objectives of the project

One of the major public health challenges worldwide is the rapidly growing number of people with dementia. More than 50 million people worldwide are living with dementia and about 70% of those are diagnosed with Alzheimer’s disease. Although a global burden – equivalent to 1% of the world's GDP – AD is particularly critical in the EU, where over 10.5 million patients live with dementia.
BRIGHT aims to develop 40 Hz flickering light therapy using novel invisible spectral flicker (ISF) that can induce brainwaves in AD patients and potentially improve cognition and potentially slow the disease progression. The light is combined in a way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The primary objective of the project is to validate the need for such a treatment, and establish the necessary partners for the clinical evaluation.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the feasibility study of Phase 1 we gathered tremendous amount of information and uncovered valuable knowledge and understanding, some of which are the following:
- User requirements addressed by subsequent new design features
- Market analysis that identified the most interesting market segment, in regards to effect, willingness and size. This sharpens our eye and approach onwards in regards to product development, strategy and IPR
- Effective and detailed national go-to-market strategy and business model to address the market segment, including supply and sales setup
- Strong partnership with key clinical partners and pilot test participants

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

With the work done in SMEi Phase 1, it is now possible to move directly forward to clinical tests, with a device at that is validated among the users, designed and optimised for regulatory approval.
Furthermore a clear plan of the implementations of the 40 Hz neuromodulation light in a business setting is prepared - Ultimately leading to potentially better health and life among the population.

Optoceutics Logo